Xenon Pharmaceuticals (STU:XP0) Receivables Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XP0 Xenon Pharmaceuticals Inc STU:XP0
27 GF Score
Price €37.80
GF Value €0.14
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Xenon Pharmaceuticals's Revenue for the three months ended in Jun. 2026 was €0.00 Mil. Xenon Pharmaceuticals's average Accounts Receivable for the three months ended in Jun. 2026 was €1.22 Mil.

Xenon Pharmaceuticals  (STU:XP0) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Xenon Pharmaceuticals Receivables Turnover Related Terms

Xenon Pharmaceuticals Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals Receivables Turnover Chart

Xenon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.96 5.35 - - 5.14

Xenon Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:XP0 vs PTCT, DNTH, MIRM: Receivables Turnover Comparison

For the Biotechnology subindustry, Xenon Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Receivables Turnover falls into.


STU:XP0
27GF Score
Xenon Pharmaceuticals Inc STU:XP0
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Xenon Pharmaceuticals's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=6.6455312157048 / ((1.4186383389667 + 1.1673549320959) / 2 )
=6.6455312157048 / 1.2929966355313
=5.14

Xenon Pharmaceuticals's Receivables Turnover for the quarter that ended in Jun. 2026 is calculated as

Receivables Turnover (Q: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2026 ) / ((Accounts Receivable (Q: Mar. 2026 ) + Accounts Receivable (Q: Jun. 2026 )) / count )
=0 / ((1.0111091824336 + 1.4248228811336) / 2 )
=0 / 1.2179660317836
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Xenon Pharmaceuticals (STU:XP0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenon Pharmaceuticals stock appears to be overvalued. The current stock price of €37.80 is trading 26900% above its estimated GF Value™ of €0.14. GuruFocus considers Xenon Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:XP0:

  • Receivables Turnover:
  • GF Value™: €0.14 vs. price of €37.80 (26900% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:XP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenon Pharmaceuticals Business Description

Other Exchanges XENE:USA
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
27GF Score

Get the complete analysis for STU:XP0

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.80
Price
€0.14
GF Value